Results 61 to 70 of about 6,463,095 (311)

Abatacept for Prophylaxis of Acute and Chronic Graft‐Versus‐Host‐Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation—A Systematic Review and Meta‐Analysis of Cohort Studies

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Graft‐versus‐host disease (GvHD) remains one of the most significant complications of hematopoietic stem cell transplantation (HSCT). Abatacept, a selective T‐cell costimulation modulator, is a relatively novel prophylactic agent, though pediatric data remain limited.
Matthijs D. Kruizinga, Anne B. Verbeek, Caroline A. Lindemans, Emilie P. Buddingh   +3 more
wiley   +1 more source

Progression-free survival (PFS) during erlotinib therapy (with 95% CI).

, 2019
Progression-free survival (PFS) during erlotinib therapy (with 95% CI).
Tim Van den Wyngaert (4330615), Paul Germonpré (6580541)   +1 more
core   +1 more source

Bone and Soft Tissue Neoplasms in Infants Versus Older Children: A Report From the Cancer in Young People in Canada Program

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background and Aims Infant bone and soft tissue neoplasms present distinct clinical challenges and lack large‐scale data to inform treatment decisions. This study aims to characterize bone and soft tissue neoplasms in infants in Canada and to compare their outcomes with those of older pediatric patients.
Samuel Sassine, Hallie Coltin, Maria Kondyli, Monia Marzouki, Nicolas Prud'homme, Nida Usmani, Rebecca J. Deyell, Lesleigh Abbott, Tony H. Truong, Sapna Oberoi, Ketan Kulkarni, Josée Brossard, Lynette Bowes, Paul Gibson, Sarah McKillop, Roona Sinha, Lillian Sung, Catherine Vezina, Laura Wheaton, Alexandra P. Zorzi, Marie‐Claude Pelland‐Marcotte, Thai Hoa Tran   +21 more
wiley   +1 more source

Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas

Endocrine Oncology
Objective: Glucagonomas are rare islet cell tumours, accounting for 2% of such tumours, with an annual incidence of 0.01–0.1 per million. This study aimed to describe diagnostic characteristics and treatment outcomes in patients with glucagonoma from a ...
Eleni Armeni, Alexander Branton, Juliana Porto, Dalvinder Mandair, Aimee R Hayes, Aspasia Manta, Shaunak Navalkissoor, Gopinath Gnanasegaran, Ann-Marie Quigley, Ashley B Grossman, Martyn Caplin, Christos Toumpanakis   +11 more
doaj   +1 more source

Impact of Initial Treatment Setting on Survival in Relapsed Pediatric and AYA Bone Sarcomas: A Secondary Analysis of a Prospective Clinical Trial

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Outcomes in relapsed or refractory pediatric and AYA bone sarcomas remain poor, and the impact of early referral to specialized sarcoma centers on survival is unclear. Early centralization of care may improve local and systemic treatment quality, but evidence in this population is limited.
Justyna Antoniuk‐Majchrzak, Katarzyna Bilska, Tomasz Koziński, Jadwiga Węcławek‐Tompol, Dorota Sega‐Pondel, Radosław Chaber, Wanda Badowska, Katarzyna Rosłan, Hanna Koseła‐Paterczyk, Anna Raciborska   +9 more
wiley   +1 more source

Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands

Health and Quality of Life Outcomes, 2012
Background Gefitinib, a tyrosine kinase inhibitor, is an effective treatment in advanced non-small cell lung cancer (NSCLC) patients with an activating mutation in the epidermal growth factor receptor (EGFR).
Verduyn S, Biesma Bonne, Schramel Franz MNH, van der Scheer Feike W, Langenfeld Merel K, de Peuter Maria A, Dingemans Anne-Marie C   +6 more
doaj   +1 more source

Progression-free survival according to the treatment field.

, 2019
Cranio-spinal irradiation tended to show better progression-free survival, although not statistically significant (p = 0.204)).
Dong-Seok Kim (128408), Chang-Ok Suh (2609776), Jung Woo Han (7460639), Seung Yeun Chung (6855611), Hong In Yoon (6855632)   +4 more
core   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

The role of Lobectomy in Glioblastoma management: A Retrospective series

Brain and Spine
Introduction: Treatment choices for glioblastoma (GB) remain scarce. Multiple clinical studies have demonstrated the importance of supramaximal resection.
Christina K. Arvaniti, Alexandros G. Brotis, Jacob S. Young, Sivani Sivanrupan, Gracia Menna, Masahiro Nishide, Philippe Schucht, Mitchel Berger, Kostas N. Fountas   +8 more
doaj   +1 more source

From mice to humans—divergent strategies for intestinal homeostasis and regeneration

FEBS Letters, EarlyView.
Recent advances such as organoid genome editing, xenotransplantation, imaging, and whole‐genome sequencing have enabled direct studies of human intestinal stem cells (ISCs). These studies reveal species‐specific features, including slower ISC proliferation, distinct injury responses, slower somatic mutation accumulation in humans, and an inverse ...
Keiko Ishikawa, Shinya Sugimoto, Toshiro Sato   +2 more
wiley   +1 more source